Palantir's NHS Grip Tightens as Fubon Opens Coverage With a Buy

British ministers are leaning toward extending Palantir's contract with the National Health Service, according to media reports, with the decisive factor being the assessment that pulling the platform out would disrupt operations too severely. The news lands as Palantir shares climb 2.9% in today's session, carried by a broader recovery in AI stocks that the AP news agency reports is propping up the US market.

For investors, the NHS story cuts to a question that goes beyond growth figures: how deeply do AI platforms embed themselves in the daily routines of their customers? The reported extension plans rest on operational dependence rather than enthusiasm. Critics continue to question how the platform is used and whether it delivers results — a tension that defines the investment case as much as any revenue line.

Binding a client tightly to your workflows is an economic advantage, but only when that client also sees durable value. In the NHS case, the deliberations reportedly center on the consequences of an exit. Judging Palantir therefore requires holding operational entrenchment and effectiveness together; watching lock-in alone understates the weight of the criticism.

Should investors sell immediately? Or is it worth buying Palantir?

Fresh Coverage, Divergent Targets

Fubon initiated coverage of Palantir yesterday with a buy rating and a price target of $200. The stock was up 1.9% premarket at €154.30. Not everyone on the sell side shares that view: RBC Capital lifted its target from $90 to $130 on November 3, while analyst Rishi Jaluria kept an "Underperform" rating, signaling expectations of below-average performance. The shares slipped after the quarterly results.

Those results gave the bulls plenty to work with. Palantir posted third-quarter 2026 revenue of $2.31 billion, up 96% year over year, with US commercial business growing 148%. Roughly a week ago the company raised its 2026 revenue guidance to $8.530–$8.534 billion, implying 91% growth, and projected 143% growth in US commercial operations.

From Announcements to Live Deployments

Recent partnerships illustrate how the company pushes its platforms into varied working environments. On November 5, Changshin and Palantir announced they would deploy Foundry and AIP in shoe development and manufacturing, tying data and artificial intelligence to planning and factory production. A company-wide partnership with AmeriLife, announced about a week ago, will put Foundry and the Artificial Intelligence Platform to work across its health and wealth distribution organizations. At Crump Life Insurance Services, related applications were already running in production, with a broader rollout under way.

What matters most is the step into live operations, which makes practical use tangible. The NHS report adds the next layer: how customers come to judge that embeddedness later on. Whether announced deployments mature into lasting business relationships is the test the growth numbers cannot answer on their own — and at the NHS, that very durability is now up for debate. An extension would be a positive for Palantir, while the criticism of usage and effectiveness names the real proving ground.

Ad

Palantir Stock: New Analysis - 11 November

Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Palantir analysis...